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Abstract
Genotyping efforts in hemophilia A (HA) populations in many countries have identified large 
numbers of unique mutations in the Factor VIII gene (F8). To assist HA researchers conducting 
genotyping analyses, we have developed a listing of F8 mutations including those listed in 
existing locus-specific databases as well as those identified in patient populations and reported in 
the literature. Each mutation was reviewed and uniquely identified using Human Genome 
Variation Society (HGVS) nomenclature standards for coding DNA and predicted protein changes 
as well as traditional nomenclature based on the mature, processed protein. Listings also include 
the associated hemophilia severity classified by International Society of Thrombosis and 
Haemostasis (ISTH) criteria, associations of the mutations with inhibitors, and reference 
information. The mutation list currently contains 2,537 unique mutations known to cause HA. HA 
severity caused by the mutation is available for 2,022 mutations (80%) and information on 
inhibitors is available for 1,816 mutations (72%). The CDC Hemophilia A Mutation Project 
(CHAMP) Mutation List is available at http://www.cdc.gov/hemophiliamutations for download 
and search and will be updated quarterly based on periodic literature reviews and submitted 
reports.
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INTRODUCTION
Hemophilia A (HA) is an X-linked inherited disorder that results in impaired blood clotting 
with subsequent bleeding. The disorder is a consequence of a mutation in the Factor VIII 
gene (F8; MIM# 300841) that leads to reduced production or inadequate function of Factor 
VIII (FVIII), a protein necessary for clotting. Because of its inheritance pattern, HA occurs 
almost exclusively in males, and it is estimated that more than 20,000 people are living with 
HA in the United States (CDC, 2012; Soucie, et al., 1998).
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Severity of HA differs based on FVIII plasma level, with <1% of the normal protein level 
conferring the most severe disease (White, et al., 2001). HA can result in joint swelling and 
damage, intracranial hemorrhage, organ damage, and death if bleeding is not prevented or 
stopped (Berntorp and Shapiro, 2012). Complications of treatment of HA include 
development of antibodies (inhibitors) to treatment products that decrease the effectiveness 
of the products to stop hemorrhages and, rarely today, infection resulting from blood product 
contamination (Berntorp and Shapiro, 2012).
Because HA is an inherited disorder, knowledge of the mutation carried in a family can aid 
in prenatal diagnosis and identification of familial carriers (Goodeve, 2008). Also, certain 
mutation types have been shown to increase the risk of developing an inhibitor (Miller, et 
al., 2012), suggesting that knowledge of the mutation could be used to in the development of 
an individualized treatment strategy to reduce the chance of an inhibitor.
F8 spans 186,000 base pairs on the X chromosome. The gene includes 26 exons and 
produces an 8 kilobase mRNA and a mature FVIII protein of 2,332 amino acids (Gitschier, 
et al., 1984). Sequencing of the F8 cDNA has revealed a repeating domain structure (A1-
A2-B-A3-C1-C2). FVIII is sensitive to proteolytic cleavage, with the majority of circulating 
FVIII consisting of heavy chains (A1, A2, and B domains) and light chains (A3, C1, and C2 
domains) (Graw, et al., 2005). During clot formation, FVIII is proteolytically cleaved at the 
A2/B junction in order to open binding sites and allow for interaction with other proteins 
important in clot formation. Thus, the B domain is believed unnecessary for protein activity 
(Ogata, et al., 2011; Pipe, 2009).
Because F8 is located on the X chromosome, HA predominately affects males who either 
inherit a mutation in F8 from their mother or develop a de novo mutation. Rarely, females 
are affected with HA as a result of skewed X-chromosome inactivation or inheritance of two 
aberrant F8 alleles from their mother and father.
Mutations reported to cause HA may be characterized by 6 mechanisms: deletion, 
duplication, insertion, insertion/deletion, inversion, and substitution. These mutation 
mechanisms can lead to a shift in the reading frame (frameshift mutation), a large structural 
change in the gene, the replacement of an amino acid with a different amino acid (missense 
mutation), the replacement of an amino acid with a premature stop codon (nonsense 
mutation), a small structural change in the gene, an alteration of a splice site, a change in the 
promoter region of the gene, or a synonymous change whose effects on the mature protein 
remain unclear. It is estimated over 40% of severe HA cases are caused by inversions within 
the F8 gene, with the next most-common mutation mechanism being substitution (Miller, et 
al., 2012).
The CHAMP Mutation list was developed in response to a need to easily identify recurrent 
and novel mutations. Several locus-specific databases for F8 are currently available, such as 
the Haemophilia A Mutation, Structure, and Test Site (HAMSTeRS), Human Gene 
Mutation Database (HGMD), and Hemobase (Kemball-Cook and Tuddenham, 1997; 
Stenson, et al., 2009; Vidal F, 2010). However, these databases are not easily searchable, 
comprehensive in their scope, specific to HA, or regularly updated. We sought to 
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systematically compile mutations known to cause HA as reported in the literature and 
elsewhere, to document them according to standardized nomenclature, to link them with 
relevant phenotypic information, and to make them easily searchable. A simple, 
comprehensive mutation list was therefore developed with information on each specific 
mutation reported to cause HA. This report describes the CDC Hemophilia A Mutation 
Project (CHAMP) Mutation List, a mutation list containing more than 2,500 F8 mutations 
reported to cause HA.
MATERIALS AND METHODS
The CHAMP Mutation List is hosted on the CDC website and can be freely accessed and 
downloaded at http://www.cdc.gov/hemophiliamutations. The mutation list is updated 
quarterly with recently-published mutations reported to cause HA.
Data Collection
In order to compile a comprehensive list of mutations reported to cause HA, F8 locus-
specific databases (HAMSTeRS, Hemobase, and HGMD) were examined. Mutations 
reported to cause HA in these databases were identified, and publications cited for these 
mutations were reviewed in order to better characterize the reported mutations. 
Subsequently, a systematic literature search was conducted to identify additional reports not 
included in any of the databases. PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) was 
searched using the following terms: hemophilia A AND mutation, factor VIII AND mutation, 
F8 AND mutation. Any studies published in peer-reviewed journals that reported HA-
associated mutations were eligible for inclusion. Finally, mutations identified as part of a 
large inhibitor surveillance effort conducted in our lab were compared to those already 
published in the literature in order to identify novel mutations. Each month, PubMed will be 
searched using the search terms described above to identify recently-reported mutations. The 
results of these searches will be combined into quarterly CHAMP Mutation List updates.
Data Extraction and Preparation
Only single mutations reported to cause HA in males were included in the CHAMP 
Mutation List, as inclusion of reports of multiple mutations causing disease and affected 
females could lead to phenotypic ambiguity. In the mutation list, each mutation is uniquely 
identified by its corresponding HGVS-standardized cDNA change. When available, the 
mutation list also provides the following additional information for each mutation: HGVS-
standardized predicted protein changes as well as a link to the widely used mature protein 
nomenclature; the exonic, codon, and domain location of the mutation; the type and subtype 
of the mutation and mechanism underlying it; the phenotypic severity associated with the 
mutation; whether or not the mutation has been reported in association with inhibitors; a link 
to an identifier of the reference reporting the mutation; the year the mutation was first 
reported; and any additional comments, such as predicted functional changes caused by the 
mutation. Each of these items is described in more detail below.
Each mutation was assigned unique identifiers for cDNA and predicted protein changes 
using HGVS-standardized nomenclature, based on cDNA reference sequence NM_000132.3 
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and protein reference sequence NP_000123.1 (www.hgvs.org/mutnomen/). Naming was 
facilitated by use of the Mutalyzer program (Wildeman, et al., 2008). Each mutation listing 
also includes historical protein nomenclature, in which numbering begins at the codon that 
represents the first amino acid of the mature, processed protein.
The type of mutation was categorized using the following terms: frameshift, large structural 
change, missense, nonsense, promoter, small structural change, splice site change, or 
synonymous. A frameshift mutation was defined as any mutation that resulted in the shift of 
the reading frame. Large structural changes were defined as changes in F8 that involved an 
area of the gene that was >50 base pairs in length. Missense mutations were defined as any 
mutations that resulted from a single amino acid substitution for another amino acid. 
Nonsense mutations were defined as any mutation that resulted in the substitution of an 
amino acid with a stop codon. Promoter mutations were defined as those mutations 
occurring before the initiation codon. Small structural changes were defined as in-frame 
changes <50 base pairs in length. Splice site changes were defined as mutations located 
within the intronic regions of F8 that were reported by the researcher to be associated with 
splice site alterations. Synonymous changes were defined as mutations that caused no 
predictable change in the protein sequence.
The subtype of each mutation identifies whether or not a mutation occurred on the heavy 
chain or light chain of F8, a mutation occurring across multiple domains or a single domain, 
or mutations within a poly A chain. The mechanism was characterized as deletion or 
duplication if a portion of the F8 sequence was deleted or duplicated. The mechanism was 
characterized as insertion if extra base pairs were inserted into the F8 sequence. If a portion 
of the F8 sequence was deleted and extra base pairs were inserted in their place, the 
mechanism was characterized as insertion/deletion. If a large region of the gene was 
inverted, the mechanism was classified as inversion. If one base was substituted for another, 
the mechanism was characterized as substitution.
Using the recommendation of the Scientific and Standardization Committees of the 
International Society on Thrombosis and Haemostasis, a phenotypic severity classification 
was assigned to each report from factor levels provided in each publication, with <1% as 
severe, 1–5% as moderate, and >5% as mild (White, et al., 2001). The severity described in 
the original report is also provided in a separate field, even if this description does not match 
the assigned severity.
The presence or absence of inhibitors reported in association with each mutation is listed if 
these data were provided in the original publication. Otherwise, the mutation’s link with 
inhibitor development is listed as ‘Not Reported’.
A Reference ID is provided for each mutation, linking to information on the first publication 
to report the mutation. If the mutation was identified through searches of the other locus-
specific databases and was listed as ‘unpublished’, the Reference ID links to a publication 
on that database.
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Mutation List Design and Implementation
The CHAMP Mutation List is a freely downloadable file. The mutation list was developed 
in Microsoft Excel 2010 but is compatible with all versions of Microsoft Excel. The file 
contains tabs providing the Table of Contents, the Mutation List, Field Definitions, 
References, Figures, Tables, Instructions for Use, and Instructions for Submissions. The 
Table of Contents tab outlines the contents of all of the tabs in the Excel workbook. The 
CHAMP Mutation List tab contains a listing of mutations reported to be associated with HA. 
The Field Definitions tab contains an explanation of all of the fields in the CHAMP 
Mutation List tab. The References tab provides a link between the Reference ID provided in 
the CHAMP Mutation List and the citation for the reporting publication. The Figures tab 
provides several summary figures produced using data from the CHAMP Mutation List. 
Similarly, the Tables tab provides several standard summary tables produced from data in 
the mutation list. Instructions for sorting the data, finding a specific mutation, and filtering 
results are provided in the Instructions tab for all versions of Excel. Instructions for 
submitting either updates to existing mutations or novel mutations are provided in the 
Submissions tab. This simple structure allows the user to download and analyze the 
mutations quickly and easily.
RESULTS AND DISCUSSION
The CHAMP Mutation List was last updated in July of 2012. The mutation list currently 
contains 2,537 unique mutations reported to cause HA. Figure 1 shows the number of novel 
mutations reported by year of publication. The number of novel mutations per year peaked 
at 424 in 2008, a year when results from several large HA studies were published.
Mutation Distributions
The distribution of mutation types is outlined in Table 1. The majority of unique mutations 
were missense mutations (49%), followed by frameshift (24%) and nonsense (11%) 
mutations. Splice site changes, large structural changes, synonymous mutations, and 
promoter mutations were the least reported mutation types (8%, 6%, 1%, and <1%, 
respectively).
The distribution of missense, frameshift, and nonsense mutations throughout F8 are shown 
in Figure 2. Each bar represents 20 codons. Nonsense and frameshift mutations are evenly 
distributed throughout F8. However, missense mutations are relatively uncommon in the B 
domain of the gene. This is to be expected, since this portion of the gene is not necessary for 
proper function of the protein. Therefore, changes to the gene that are not expected to affect 
the downstream portion of the gene should not cause loss of function (Ogata, et al., 2011). 
Supp. Figure S1 shows the number of mutations per codon across each of the F8 domains. 
Again, it can be noted that missense mutations are relatively infrequent in the B domain. In 
the other major domains missense mutations are reported to occur at a frequency 
approaching 1 per codon.
As stated above, 6% of mutations are reported to be large structural changes. A large 
percentage of those (82%) are large deletions that span one or more FVIII domains, with the 
remaining mutations being inversions and large duplications. The distribution of these 
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mutations throughout the gene is shown in Figure 3. These large deletions range from small, 
single-domain deletions to large, whole-gene deletions.
Mutations and Severity
Factor level associated with the HA caused by the mutation was reported for 2,022 
mutations (80%). The majority of mutations (n=1,178) were associated only with severe 
HA. Only moderate HA was reported for 294 mutations, and only mild HA for 398 
mutations. Variable severity was reported for 152 mutations (7.5%). The distribution of 
mutations associated with mild, moderate, and severe HA throughout F8 is shown in Figure 
4. The distributions of mild- and moderate-associated mutations are similar, with few 
mutations associated with mild or moderate disease mapped to the B domain. However, 
severe-associated mutations are relatively evenly distributed throughout the gene. This is 
likely due to the fact that many of the mutations causing severe disease are nonsense or 
frameshift mutations that prematurely truncate the gene product.
Mutations and Inhibitors
Information on whether or not a mutation was associated with inhibitor development was 
recorded for 1,816 mutations (72%) (Table 2). Of these, 353 (19%) have been observed in 
patients with inhibitors. Large structural changes are disproportionately associated with 
inhibitors. For example, 70% of large deletion mutations have been associated with 
inhibitors.
The distribution of the inhibitor-associated mutations throughout F8 is shown in Figure 5. 
Mutations associated with inhibitors are more heavily clustered in the light chain of the 
gene. Of 293 mutations located in the C1 and C2 domains, 61 (20.8%) have been reported in 
association with inhibitors versus 204 of 1,302 mutations located outside the C1 and C2 
domains (15.7%) (P=0.03).
CONCLUSIONS
The CHAMP Mutation List is the most comprehensive, freely-accessible listing of F8 
mutations reported to cause HA available to date. It has approximately 1,300 more novel 
mutations than the current version of HAMSTeRS (Kemball-Cook and Tuddenham, 1997). 
This new resource allows researchers to easily search and analyze mutations in F8 that are 
known to be associated with HA by providing them with information regarding their 
location within F8, their associated severity of disease and their association with disease-
complicating inhibitors. Researchers can also use the resource to study mutation 
distributions, such as the analyses provided in this report.
After its launch in 1996, HAMSTeRS became a useful tool for investigators to assess the 
novelty of identified mutations or their previous associations with disease. However, the 
structure of the database has not been updated since 2007, one year before the peak of novel 
mutation reporting. The database does not use unique identifiers for mutations, such as 
HGVS cDNA nomenclature. This leads to some ambiguity, particularly regarding large 
deletions and point mutations occurring within the same codon. Summary analyses of 
mutation distributions become difficult because of this ambiguity as well as the ambiguity 
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arising from multiple reports of the same mutation. Because the CHAMP Mutation List has 
been designed to include only a single listing of a mutation with a unique identifier, it is 
hoped that this ambiguity will be diminished.
Several non-locus-specific databases such as the Database for Single Nucleotide 
Polymorphisms (dbSNP) (Sherry, et al., 2001) and HGMD (Stenson, et al., 2009) compile 
reported mutations within F8. However, the location of the mutations within F8 and their 
relative location to codons and domains is not always intuitive. Limited information 
regarding the severity of HA associated with mutations or their association with inhibitor 
development is available, unless one wishes to link to the original publication.
The CHAMP Mutation List provides comprehensive information regarding mutation 
location, severity of disease reported to be associated with mutations, and whether or not the 
mutations have been associated with inhibitor development, as well as providing a reference 
to the original publication. The CHAMP Mutation List does have some limitations. In the 
majority of large deletions and duplications reported, exact break points have not been 
determined. It is therefore not possible to distinguish which reported mutations are identical 
and which are only similar. We have included in the Mutation List a single record for each 
deletion or duplication described only at the exon level. The true number of unique deletions 
and duplications is likely to be underestimated. Similarly, we have excluded mutation 
reports in which more than one mutation was reported to be associated with a patient’s HA, 
as the severity and inhibitor associations would be ambiguous. It is possible this could lead 
to an under-reporting of mutations. However, reporting of more than one mutation causing a 
patient’s hemophilia was rare. For example, fewer than 30 mutations out of close to 1200 
mutations reported in HAMSTeRS were seen in combination with another mutation. Also, 
because updates to the mutation list are based on literature reviews, unpublished mutations 
would not be included in the Mutation List. However, we have provided a mechanism for 
researchers to provide information on unpublished mutations. Finally, since the frequencies 
given in this report are frequencies of mutations and not of patients, they cannot be used as 
predictors of patient outcomes. As previously stated, it is estimated over 40% of severe HA 
cases are caused by inversions; however, the CHAMP Mutation List only includes 2 listings 
for inversions, illustrating the limitations of extrapolating the frequency of a particular 
mutation type to frequencies of patients affected by that mutation type. We are currently 
working to coordinate a list of F8 mutations observed in the United States as well as those 
observed worldwide in population-based studies of HA.
The CHAMP Mutation List was designed to combine information on the location of 
mutations throughout F8 as well as information on their association with severity of HA and 
complicating inhibitors. It is hoped this resource will help researchers and clinicians better 
understand the molecular etiology of HA and foster scientific collaboration.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Novel F8 mutations by year of publication.
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Figure 2. 
Distribution of missense, frameshift, and nonsense mutations in F8.
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Figure 3. 
Reported large deletions in F8.
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Figure 4. 
Distribution of mutations associated with mild, moderate, and severe HA throughout F8. 
Classes of mutations include missense, nonsense, frameshift, promoter, in-frame, and 
synonymous mutations.
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Figure 5. 
Distribution of mutations associated with inhibitors across F8.
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